Market narrative
Move between stock news, official company releases, crypto, and FX without losing the path back to ticker research.
Key takeaways: Secure AI acceleration: Organizations can confidently adopt and scale AI technologies safely and prevent data exposure. Zero-disruption protection: The solution secures users across existing browsers, SaaS platforms, and desktop applications, without changing the network architecture or impacting the user experience.
Press releases
BOSTON--(BUSINESS WIRE)--Dynatrace (NYSE: DT), the leading AI-powered observability platform, today announced financial results for the first quarter of fiscal 2027 ended June 30, 2026. "Dynatrace delivered an exceptional quarter, led by 41% organic net new ARR growth,"1 said Rick McConnell, Chief Executive Officer of Dynatrace. "Demand continues to strengthen as enterprises expand cloud-native workloads and accelerate their AI initiatives. As software becomes increasingly AI-driven, customers.
LOS ANGELES, Aug. 05, 2026 (GLOBE NEWSWIRE) -- EVgo Inc. (NASDAQ: EVGO) (“EVgo” or the “Company”), one of the nation's largest providers of public fast charging infrastructure for electric vehicles (EVs), announced plans to add “EVgo Superchargers” to its metropolitan network. The V4 Superchargers are capable of up to 500kW / 1000 Volts, bringing more fast charging choices to EV drivers.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2026. Total revenues in the second quarter of 2026 decreased by two percent year-over-year to $783.3 million, compared to $798.6 million in the second quarter of 2025. “We just submitted what we believe are two of the most important NDAs in rare pulmonary disease history: ralinepag t.
TAMPA, Fla.--(BUSINESS WIRE)--Bloomin' Brands, Inc. (Nasdaq: BLMN) today reported results for the second quarter 2026 (“Q2 2026”) compared to the second quarter 2025 (“Q2 2025”). CEO Comments “I am pleased with our financial results in the second quarter and our continued progress on the Outback Turnaround, which has led us to raise our full year earnings guidance,” said Mike Spanos, CEO. “We remain focused on consistency of execution across food, service, experience, and affordability to deliv.
U.S. Net Rooms Growth Improved for the Second Consecutive Quarter, Supporting 2.6% Global Net Rooms Growth NORTH BETHESDA, Md., Aug. 5, 2026 /PRNewswire/ -- Choice Hotels International, Inc. ("Choice" or "the Company") (NYSE: CHH), a leading global lodging franchisor with an asset-light model, today reported results for the second quarter ended June 30, 2026.
Delivers ~15% Net Sales Growth Raises 2026 Net Sales and Adjusted EBITDA Outlook Updates Long-Term Adjusted Gross Margin Target to >49%
Broadridge's unified governance platform enables xStocks holders to submit voting preferences for shares underpinning their tokenized equities, closing one of the clearest gaps between tokenized equities and traditional stock ownership NEW YORK, Aug. 5, 2026 /PRNewswire/ -- Broadridge Financial Solutions, Inc., (NYSE: BR), a global Fintech leader, today announced Broadridge's unified governance platform will support shareholder communications and proxy voting for eligible holders of xStocks, the industry-leading tokenized equities framework developed by Payward Services, the B2B infrastructure platform from Payward. "The endgame for tokenization was never just building faster programmable capital markets.
MERRILLVILLE, Ind.--(BUSINESS WIRE)--NiSource Inc. (NYSE: NI) today announced, on a GAAP basis, net income available to common shareholders for the quarter ended June 30, 2026 of $45.5 million, or $0.09 of earnings per diluted share, compared to net income available to common shareholders of $102.2 million, or $0.22 of earnings per diluted share, for the same period of 2025. For the six months ended June 30, 2026, on a GAAP basis, NiSource's net income available to common shareholders was $556.
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Delek US Holdings, Inc. (NYSE: DK) (“Delek US”, "Company") today announced financial results for its second quarter ended June 30, 2026. “Our second quarter results demonstrate the tangible progress we are making in strengthening Delek's free cash flow profile” said Avigal Soreq, President and Chief Executive Officer of Delek US. “Following the successful completion of the Big Spring refinery turnaround in the first quarter, Big Spring ran well during the seco.
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Delek Logistics Partners, LP (NYSE: DKL) ("Delek Logistics") today announced its financial results for the second quarter 2026. “Delek Logistics delivered another strong quarter in 2026, underscoring the durability of our integrated crude, gas, and water platform and the growing contribution from third-party cash flows. As we continue positioning Delek Logistics for long-term success, we are pleased to announce that Mark Hobbs has transitioned into the role of.
Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated targets for drug discovery REC-4881 (MEK1/2 inhibitor): Additional Phase 2 data in Familial Adenomatous Polyposis (FAP) to be presented at the Presidential Plenary session at leading hereditary GI annual meeting in November 2026 REC-7735 (PI3Kα H1047R inhibitor): IND cleared, Phase 1/2 trial start in 2H26; a >100× mutant-selective PI3Kα H1047R inhibitor designed to improve therapeutic index by enabling deep suppression of the most common activating PI3Kα mutation while sparing wild-type PI3Kα Reduced 2026 cash operating expense guidance to 100-fold selectivity for the H1047R mutant over wild type in order to drive high, sustained target inhibition while avoiding hyperinsulinemia-driven reactivation The differentiated development candidate was delivered in 10 months and 242 compounds from first novel hit through Recursion's AI-native design platform, demonstrating the Company's ability to rapidly translate platform insights into optimized clinical candidates With the IND cleared, the Phase 1/2 ZINNIA clinical study for patients with select PIK3CA H1047R-mutant solid tumors will be initiated in the second half of 2026 For the rest of the portfolio, programs continue to progress as planned. Additional expected upcoming milestones across Recursion's internal pipeline: REC-1245 (RBM39): Additional Phase 1 dose escalation data expected in 2H26 REC-617 (CDK7): Early Phase 1 safety and PK combination data expected in 1H27 REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27 REC-4539 (LSD1): Early Phase 1 safety and PK monotherapy data expected in 2H27 Agentic AI is compounding Recursion's advantage across Biology, Design, and ClinTech: Target Discovery Agent pairs frontier AI reasoning with Recursion's proprietary multimodal maps to surface novel drug targets, enabling scientists to mine and extract insights from proprietary maps in hours rather than weeks.
Q4 sales of $737 million increased 43 percent and 42 percent on a reported and organic basis, respectively Q4 earnings per diluted share (EPS) of $2.91 and record adjusted EPS of $2.96 FY26 EPS of $4.42 and record adjusted EPS of $4.57 Company provides FY27 Q1 and annual Outlook PITTSBURGH, Aug. 5, 2026 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) (the "Company") today announced fourth quarter and fiscal 2026 results. "Our team delivered strong fiscal 2026 results, reflecting volume from improving market conditions and our strategic growth initiatives," said Sanjay Chowbey, President and CEO.
Austin, Aug. 05, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Monoethylene Glycol Market was valued at USD 28. 38 billion in 2025 and is projected to reach USD 50. 63 billion by 2035, expanding at a CAGR of 5.
HANOVER, Pa.--(BUSINESS WIRE)--Utz Brands, Inc. (NYSE: UTZ) (“Utz” or the “Company”), a leading U.S. manufacturer of branded Salty Snacks and a small-cap growth and value Staples equity, today reported financial results for the Company's second fiscal quarter ended June 28, 2026. 2Q'26 Summary(1) Net Sales increased 1.4% to $371.8 million Total Organic Net Sales increased 1.4%; Branded Salty Snacks Organic Net Sales increased 3.3% Gross Profit Margin decrease of 10bps Adjusted Gross Profit Marg.
Vancouver, British Columbia--(Newsfile Corp. - August 5, 2026) - Cabral Gold Inc. (TSXV: CBR) (OTCQX: CBGZF) ("Cabral" or the "Company") is pleased to announce that it has appointed Mr. Elton Pereira as Vice President Exploration, effective immediately.
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2026 Financial Results: Revenue of $1,368 million, an increase of 10% year-over-year; 8% organic constant currency growth Reported Net Income of $54 million, Adjusted Net Income of $174 million Adjusted EBITDA of $288 million; Adjusted EBITDA Margin of 21.2% Reported EPS of $0.11, Adjusted EPS of $0.34 Net leverage ratio of 3.1x Adjusted EBITDA Full Year 2026 Guidance: Raising innovation revenue target to $1.25 billion Raising revenue guidance to $5.09 billion to $5.14 billion, or 6% to 7% organic constant currency growth Raising Adjusted EBITDA to $1.01 billion to $1.035 billion, a year-over-year increase of 13% at midpoint Raising Adjusted EPS to $1.10 to $1.16, a year-over-year increase of 20% at midpoint Improving year-end net leverage ratio target to approximately 3.0x Adjusted EBITDA INDIANAPOLIS, Aug. 5, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the second quarter of 2026, provided guidance for the third quarter of 2026, and updated guidance for the full year 2026. "Elanco's second quarter results demonstrate our momentum and leadership in the attractive animal health industry," stated Jeff Simmons, President and CEO of Elanco.
CVS Pharmacy offers all FDA approved GLP-1s, whether through insurance or cash-pay options. New collaboration with Eli Lilly and Company will provide eligible Zepbound and Foundayo patients an additional access point at CVS Pharmacy through the CVS Health app MinuteClinic digital weight loss visits lowered to $29, the most affordable option in the market, available 24/7 Combines an online visit with a licensed clinician, same-day medication pickup at 9,000 local CVS Pharmacy locations, and in-person pharmacist support in one connected experience, with no membership or recurring monthly fee Connected businesses position CVS Health to address opportunities and deliver novel solutions in this rapidly growing category, regardless of how the prescription is reimbursed or how the consumer gets their medicine WOONSOCKET, R.I.
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Zillow Group, Inc. (NASDAQ:Z, ZG) and certain of the Company's senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws. If you invested in Zillow, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/zillow-class-action-lawsuit.
SINGAPORE and SHANGHAI, Aug. 05, 2026 (GLOBE NEWSWIRE) -- H World Group Limited (NASDAQ: HTHT and HKEX: 1179) (“H World”, “we” or “our”) a key player in the global hotel industry, today announced that it will schedule to release its unaudited financial results for the second quarter and interim of 2026 on Monday, August 17, 2026 (Hong Kong time), after the trading hours of The Stock Exchange of Hong Kong Limited and before the opening of the U.S. market.
